Key facts
- This page summarizes Chad M. Robins's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
- 8 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 19 Aug 2026, 20:15.
Chad M. Robins - 17 Aug 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)
- Reporting relationship
- CEO and Chairman, Director
- Issuer ticker
- ADPT
- Reported as of
- 17 Aug 2026
- Net transaction value
- -$14,882,166
- SEC form
- 4
- Accepted by SEC
- 19 Aug 2026, 20:15:10 UTC
- Prior SEC filing
- 08 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Chad M. Robins filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 19 Aug 2026.
Change
- Previous filing in this sequence was filed on 08 Apr 2026.
- Current net transaction value: -$14,882,166.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001780649
Primary reporting owner
ROBINS CHAD M
- Relationship
- CEO and Chairman, Director
- Address
- C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE
- Signature
- /s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact
- Signature date
- 19 Aug 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +321,324
- Change %
- +15%
- Price
- $6.55*
- Shares after
- 2,501,842
- Date
- 17 Aug 2026
- Ownership
- Direct
ADPT
transaction
Common Stock
Sale
- Transaction value
- $7,995,479
- Shares
- -318,799
- Change %
- -13%
- Price
- $25.08
- Shares after
- 2,183,043
- Date
- 17 Aug 2026
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Sale
- Transaction value
- $64,564
- Shares
- -2,525
- Change %
- -0.12%
- Price
- $25.57
- Shares after
- 2,180,518
- Date
- 17 Aug 2026
- Ownership
- Direct
- Footnotes
- F2
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +278,676
- Change %
- +13%
- Price
- $6.55*
- Shares after
- 2,459,194
- Date
- 18 Aug 2026
- Ownership
- Direct
ADPT
transaction
Common Stock
Sale
- Transaction value
- $6,816,995
- Shares
- -278,472
- Change %
- -11%
- Price
- $24.48
- Shares after
- 2,180,722
- Date
- 18 Aug 2026
- Ownership
- Direct
- Footnotes
- F3
ADPT
transaction
Common Stock
Sale
- Transaction value
- $5,129
- Shares
- -204
- Change %
- -0.01%
- Price
- $25.14
- Shares after
- 2,180,518
- Date
- 18 Aug 2026
- Ownership
- Direct
- Footnotes
- F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -321,324
- Change %
- -54%
- Price
- $0.000000*
- Shares after
- 278,676
- Date
- 17 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 321,324
- Exercise price
- $6.55
- Footnotes
- F5
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -278,676
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 18 Aug 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 278,676
- Exercise price
- $6.55
- Footnotes
- F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 to $25.50, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F2
The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.52 to $25.64, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F3
The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.12 to $25.12, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F4
The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions all at $25.14. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F5
The option was fully vested and exercisable and would have expired on February 7, 2028.